Elomaa, Hanna
Ahtiainen, Maarit
Väyrynen, Sara A.
Ogino, Shuji http://orcid.org/0000-0002-3909-2323
Nowak, Jonathan A.
Lau, Mai Chan
Helminen, Olli
Wirta, Erkki-Ville http://orcid.org/0000-0002-2255-6136
Seppälä, Toni T.
Böhm, Jan
Mecklin, Jukka-Pekka
Kuopio, Teijo
Väyrynen, Juha P. http://orcid.org/0000-0002-8683-2996
Funding for this research was provided by:
Emil Aaltosen Säätiö (220022K)
Syöpäsäätiö (59-5619)
Article History
Received: 11 October 2022
Revised: 14 March 2023
Accepted: 15 March 2023
First Online: 31 March 2023
Competing interests
: JAN reports grants from NanoString, Akoya Biosciences and Illumina outside the submitted work. TTS is the CEO and co-owner of Healthfund Finland Oy and reports interview honoraria from Boehringer Ingelheim Finland and Amgen Finland. The other authors declare that they have no conflicts of interest.
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the hospital administration and the ethics board (Dnro13U/2011, 1/2016 and 8/2020) and the National Supervisory Authority for Welfare and Health (Valvira). The need to obtain informed consent from the study patients was waived (Valvira Dnro 3916/06.01.03.01/2016).